海航基礎(600515.SH):華融海南申請公司重整
格隆匯1月30日丨海航基礎(600515.SH)公佈,2021年1月29日,公司收到海南省高級人民法院送達的《通知書》,因公司不能清償到期債務,且明顯缺乏清償能力,中國華融資產管理股份有限公司海南省分公司(以下簡稱“華融海南”或“申請人”)已向法院提出對公司進行重整的申請。
根據上海證券交易所《股票上市規則》第13.4.1條的相關規定,如果法院依法受理申請人對公司重整的申請,公司股票將被實施退市風險警示。
如果法院正式受理對公司的重整申請,公司存在因重整失敗而被宣吿破產的風險。如果公司被宣吿破產,公司將被實施破產清算,根據《股票上市規則》第13.4.14條的規定,公司股票將面臨被終止上市的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.